- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02727751
A Long-Term Safety Study of Tenapanor for the Treatment of IBS-C (T3MPO-3)
August 25, 2020 updated by: Ardelyx
An Open Label Long-Term Safety Study of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
This phase 3, open label study will evaluate the safety of tenapanor 50 mg BID in subjects with constipation-predominant irritable bowel syndrome (IBS-C) defined by the ROME III criteria.
Subjects who have completed either TEN-01-301 (16 weeks) or TEN-01-302 (26 weeks) studies may be enrolled.
Subjects will take tenapanor for approximately 52-55 weeks total based on previous protocol and this study.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
During the treatment period of up to 39-weeks, subjects will return for study visits approximately every 13 weeks.
Subjects will undergo safety assessments at these visits, which may include a physical exam, ECG, vital signs, and clinical labs.
Adverse events and concomitant medications will be recorded.
Medication compliance will be monitored and the subjects will be given additional study drug as appropriate.
Study Type
Interventional
Enrollment (Actual)
312
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Miami, Florida, United States
- Ardelyx Clinical Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 73 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects completed all 16 weeks of TEN-01-301 or all 26 weeks of TEN-01-302
- Subject demonstrated adequate compliance with the study procedures during either the TEN-01-301 or TEN-01-302 studies
- Females must be of non-childbearing potential; If of child-bearing potential, must have negative pregnancy test and confirm the use of one of the appropriate means of contraception
- Males must agree to use appropriate methods of barrier contraception or have documented surgical sterilization
Exclusion Criteria:
- Subject has been withdrawn or discontinued prematurely from either TEN-01-301 or TEN-01-302
- The subject reports using any prohibited medication and is not willing to abide by the restrictions for intake
- Pregnant or lactating women
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 50mg BID
Tenapanor, 50 mg BID (100 mg total)
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Events in >2% Patients
Time Frame: 52-55 weeks
|
Safety assessments will be based on adverse events, clinical laboratory tests, vital signs, ECG, and physical exams
|
52-55 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2016
Primary Completion (Actual)
October 1, 2017
Study Completion (Actual)
October 1, 2017
Study Registration Dates
First Submitted
March 23, 2016
First Submitted That Met QC Criteria
March 30, 2016
First Posted (Estimate)
April 5, 2016
Study Record Updates
Last Update Posted (Actual)
September 9, 2020
Last Update Submitted That Met QC Criteria
August 25, 2020
Last Verified
August 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TEN-01-303
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Constipation Predominant Irritable Bowel Syndrome
-
Vasily IsakovRussian Science Foundation; Azbuka vkusa; Federal Research Centre of Nutrition...CompletedIrritable Bowel Syndrome With Constipation | Constipation-predominant Irritable Bowel SyndromeRussian Federation
-
Universidad Autonoma de ChihuahuaNot yet recruitingIrritable Bowel Syndrome | Constipation-predominant Irritable Bowel Syndrome | Diarrhea- Irritable Bowel Syndrome
-
usMIMA S.L.University of York; County Durham and Darlington NHS Foundation TrustNot yet recruitingConstipation | Constipation-predominant Irritable Bowel Syndrome | Constipation - Functional | Constipation Chronic Idiopathic | Constipation; Neurogenic
-
Cairo UniversityRecruitingConstipation-predominant Irritable Bowel SyndromeEgypt
-
ArdelyxCompletedConstipation Predominant Irritable Bowel SyndromeUnited States
-
Isfahan University of Medical SciencesCompletedIrritable Bowel Syndrome Predominant ConstipationIran, Islamic Republic of
-
Cedars-Sinai Medical CenterTakeda Pharmaceuticals North America, Inc.CompletedConstipation-predominant Irritable Bowel SyndromeUnited States
-
AlizymeTerminatedConstipation-Predominant Irritable Bowel SyndromeUnited States
-
Hong Kong Baptist UniversityNot yet recruitingConstipation-predominant Irritable Bowel Syndrome
-
ArdelyxCompletedConstipation Predominant Irritable Bowel SyndromeUnited States
Clinical Trials on Tenapanor
-
ArdelyxCompletedHyperphosphatemia | Chronic Kidney Disease Requiring Chronic DialysisUnited States
-
ArdelyxRecruitingIrritable Bowel Syndrome With Constipation (IBS-C)United States
-
Kyowa Kirin Co., Ltd.CompletedHyperphosphatemiaJapan
-
ArdelyxRecruiting
-
ArdelyxEnrolling by invitationIrritable Bowel Syndrome With Constipation (IBS-C)United States
-
Kyle Staller, MD, MPHArdelyxRecruitingIBS - Irritable Bowel Syndrome | IBSUnited States
-
ArdelyxCompletedConstipation Predominant Irritable Bowel SyndromeUnited States
-
ArdelyxAstraZenecaCompletedHealthy VolunteerUnited States
-
ArdelyxCompletedConstipation Predominant Irritable Bowel SyndromeUnited States
-
ArdelyxCompleted